Ypsomed 2004/05 business year

Press Releases Ypsomed Group

Burgdorf - In the 2004/05 business year Ypsomed achieved new highs in terms of sales, profit and investments. The Ypsomed Group's consolidated sales rose 21.7% to CHF 241.8 million. In the core business (pen systems, pen needles and Ypsotec) sales even increased by 42.8%. Particularly pleasing was a 157.8% rise in operating profit to CHF 47.5 million, representing an operating profit margin of 19.7%.

Leer más...

Ypsomed AG and Safety Syringes, Inc. Announce Collaboration in the Development of a Reusable Autoinjector for the UltraSafe Drug Delivery System

Press Releases Ypsomed Group

Burgdorf - Ypsomed AG in collaboration with Safety Syringes, Inc. has designed a reusable Autoinjector specifically for use with the UltraSafe Drug Delivery Systems by Safety Syringes, Inc.

Leer más...

Ypsomed to focus on innovative pen-systems and pen-needles

Press Releases Ypsomed Group

Burgdorf - Ypsomed, the leading independent developer and manufacturer of custom-made injection pens for pharmaceutical and biotech companies, and one of the leading suppliers of pen needles, is focusing future investments on its core business.

Leer más...

Issue price of Ypsomed shares set at CHF 68.00

Press Releases Ypsomed Group

Burgdorf - OptiClik, developed and manufactured by Ypsomed, is the first "semi-disposable" insulin pen-system now launched by Sanofi-Aventis for its long-acting insulin Lantus in the US market. The market launch of OptiClik is a major milestone within Ypsomed's growth strategy.

Leer más...

Issue price of Ypsomed shares set at CHF 68.00

Press Releases Ypsomed Group

Burgdorf-The offering of shares in Ypsomed Holding AG attracted high investor interest and was 7.6 times covered. The issue price for one registered share in Ypsomed Holding AG was set at CHF 68.00. Shares will be trading on the SWX Swiss Exchange for the first time today.

Leer más...